about
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central n...
Read More
21.60
0.20
(0.93%)
1.0M
XNAS Volume
XNAS 29 May, 2026 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Neutral
Alumis Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..